Skip to main content

Table 1 Clinical features of 234 cases with non-alcoholic fatty liver disease (NAFLD)

From: A case–control study on the effect of metabolic gene polymorphisms, nutrition, and their interaction on the risk of non-alcoholic fatty liver disease

Clinical parameters

Cases (mean ± SDa)

Weight (kg)

84.11 ± 16.96

Height (m)

1.70 ± 0.09

Waist length (cm)

100.87 ± 11.44

Obesity (BMI >30 kg/m2)

98 (34 %)

Diabetes [n (%)]

41 (14 %)

Hypertension [n (%)]

93 (32 %)

Glucose level (mg/dl)

97.73 ± 32.43

Fasting insulin level (mmol/l)

15.85 ± 10.87

HOMA score

3.88 ± 3.34

HOMA score >2.5 [n (%)]

117 (40 %)

Total cholesterol (mg/dl)

196.25 ± 47.18

HDL (mg/dl)

46.96 ± 11.51

Hypercholesterolemia [n (%)]

124 (43 %)

Triglyceride level (mg/dl)

145.68 ± 82.94

Hypertriglyceridemia [n (%)]

101 (35 %)

MS ATP IIIb [n (%)]

64 (22 %)

AST (IU/l)

38.65 ± 33.49

ALT (IU/l)

55.91 ± 40.58

AST/ALT ratio

0.85 ± 0.68

AST/ALT ratio ≥1.0 [n (%)]

48 (17 %)

GGT (IU/l)

67.33 ± 88.06

Alkaline phosphatase (IU/l)

174.58 ± 83.45

Total bilirubin (μmol/l)

1.11 ± 1.64

Albumin (g/dl)

4.49 ± 0.45

INR

1.08 ± 0.31

PLT (×103/ml)

232.79 ± 72.24

  1. aStandard deviation
  2. bMetabolic syndrome—Adult Treatment Panel III (ATP III) criteria: abdominal obesity, waist circumference >102 cm (men) or >88 cm (women); hyperglycemia, fasting blood glucose ≥110 mg/dl or previously diagnosed type 2 diabetes; hypertriglyceridemia, triglycerides ≥150 mg/dl or current treatment for this abnormality; hypertension, blood pressure ≥130/≥85 mmHg or treatment for previously diagnosed hypertension); and low HDL cholesterol, <40 mg/dl (men) or <50 mg/dl (women) or specific treatment for this abnormality). Patients meeting >3 of these criteria were considered to have the metabolic syndrome
Back to article page

Genes & Nutrition

ISSN: 1865-3499

Contact us